Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide

A technology of Bacteroides fragilis and capsular polysaccharide, applied in the field of probiotics, can solve the problems of unsatisfactory treatment effect of patients

Active Publication Date: 2022-07-05
GUANGZHOU ZHIYI PHARMA INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These anti-anxiety drugs will basically cause patients with different degrees of gastrointestinal discomfort, headache, dizziness, drowsiness, fatigue and other adverse reactions; and the treatment effect of a considerable number of patients is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide
  • New application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide
  • New application of bacteroides fragilis zwitterionic capsular polysaccharide or/and modified zwitterionic capsular polysaccharide

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0080] In some of the embodiments, in step 2), the preparation method of the sulfated reagent includes the following steps: under the conditions of -15 to -10 °C and vigorous stirring, to anhydrous pre-cooled to 0-4 °C Chlorosulfonic acid is added dropwise to the pyridine, and the volume ratio of the chlorosulfonic acid to the anhydrous pyridine is 1:5-10 to obtain a sulfuric acid esterification reagent.

[0081] In some of these embodiments, in step 2), the volume ratio of the suspension to the esterification reagent is 1:2-6;

[0082] In some of the embodiments, in step 2), the conditions for the sulfuric esterification reaction are: 60-90° C. for continuous stirring for 2-4 hours;

[0083] In some of these embodiments, the conditions of the flowing water dialysis in step 2) are: using a 3-10KD dialysis membrane for flowing water dialysis for 24-36 hours; the volume concentration of the ethanol aqueous solution is 80-90%, and the ethanol The time for precipitation of the aq...

Embodiment 1

[0098] Example 1. Preparation of Bacteroides fragilis capsular polysaccharide A

[0099] (1) Streak the strain of Bacteroides fragilis ZY-312 on a blood plate, culture it anaerobically for 48 hours, select a single colony and inoculate it in a plant-derived peptone liquid medium for 8 hours of fermentation (temperature is 37°C), and the obtained bacteria The liquid was centrifuged at 3000 r / min for 15 min, the supernatant was removed, and the precipitate was collected to obtain Bacteroides fragilis ZY-312 bacterial slurry.

[0100] (2) Take 50 g of the bacteria mud prepared in step (1), add 300 g of purified water to resuspend the bacteria, adjust its pH to 3.5 with 1 mol / L hydrochloric acid solution, extract at 100 ° C for 1.5 h, cool to room temperature, and centrifuge at 12000 g at room temperature for 10 min , take the supernatant to get the crude sugar solution.

[0101] (3) The crude sugar solution is concentrated by ultrafiltration through a 10KD ultrafiltration membra...

Embodiment 2

[0105] Example 2. Preparation of sulfated B. fragilis zwitterionic capsular polysaccharide

[0106] (1) The B. fragilis zwitterionic capsular polysaccharide (capsular polysaccharide A) prepared in Example 1 is prepared into a B. fragilis capsular polysaccharide suspension with a concentration of 10 mg / mL with dimethyl sulfoxide;

[0107] (2) adding a sulfating reagent to the suspension obtained in step (1) (the volume ratio of the suspension to the sulfating reagent is 1:2), stirring continuously at 90° C. for 2 h, cooling, adjusting the pH to neutrality, and centrifuging, Collect the supernatant, dialyze the supernatant with a 3KD dialysis membrane under flowing water for 28 hours, then precipitate with an 80% ethanol aqueous solution at 4°C for 12 hours, centrifuge, collect the precipitate, and freeze-dry to obtain a freeze-dried powder;

[0108] (3) The lyophilized powder obtained in step (2) was dissolved in 20 mM Tris-HCl buffer (pH 8.0), and purified by ion exchange chroma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Weight average molecular weightaaaaaaaaaa
Weight average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides novel application of bacteroides fragilis zwitterionic capsular polysaccharide or / and modified zwitterionic capsular polysaccharide. Mainly relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs, the preservation number of the bacteroides fragilis is CGMCC NO.10685, and the capsular polysaccharide extract is an extract of capsular polysaccharide A. The invention further relates to application of the capsular polysaccharide extract of bacteroides fragilis in preparation of anti-anxiety drugs. Compared with the prior art, the invention has the following beneficial effects: the inventor of the invention finds that the capsular polysaccharide A extract of Bacteroides fragilis ZY312 has an obvious effect on anxiety disorder, and the effect is verified by carrying out elevated cross maze behavioral determination and open field experiments on a rat model.

Description

technical field [0001] The invention relates to the technical field of probiotics, in particular to a new application of a zwitterionic capsular polysaccharide or / and a modified zwitterionic capsular polysaccharide of Bacteroides fragilis. Background technique [0002] Anxiety is a basic human emotion developed by human beings in the process of fighting against the environment and adapting to survival. Anxiety does not mean that it is a pathological emotion of clinical significance. It only has certain pathological characteristics and affects normal social functions. When it becomes pathological anxiety, that is, anxiety disorder. The DSM-5 defines anxiety disorders as "disorders that share characteristics of excessive fear and anxiety, and associated behavioral disturbances." Various anxiety disorders can be distinguished by differences in the types of problems or situations that lead to fearful, anxious, or avoidant behaviors and accompanying cognitive perceptions, includ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/715A61K35/741A61P25/22
CPCA61K31/715A61K35/741A61P25/22Y02A50/30
Inventor 易晓敏李永霞梁德宝智发朝
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products